These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33148490)

  • 1. 2-Aminothiazole: A privileged scaffold for the discovery of anti-cancer agents.
    Wan Y; Long J; Gao H; Tang Z
    Eur J Med Chem; 2021 Jan; 210():112953. PubMed ID: 33148490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Applications of Benzimidazole as a Privileged Scaffold in Drug Discovery.
    Guo Y; Hou X; Fang H
    Mini Rev Med Chem; 2021; 21(11):1367-1379. PubMed ID: 32753010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and evaluation of 2-aminothiazole derivatives as sphingosine kinase inhibitors.
    Vogt D; Weber J; Ihlefeld K; Brüggerhoff A; Proschak E; Stark H
    Bioorg Med Chem; 2014 Oct; 22(19):5354-67. PubMed ID: 25150091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Overview on Synthetic 2-Aminothiazole-Based Compounds Associated with Four Biological Activities.
    Farouk Elsadek M; Mohamed Ahmed B; Fawzi Farahat M
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33800023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indole: A privileged scaffold for the design of anti-cancer agents.
    Wan Y; Li Y; Yan C; Yan M; Tang Z
    Eur J Med Chem; 2019 Dec; 183():111691. PubMed ID: 31536895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
    Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
    Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiazole in the targeted anticancer drug discovery.
    Ayati A; Emami S; Moghimi S; Foroumadi A
    Future Med Chem; 2019 Aug; 11(15):1929-1952. PubMed ID: 31313595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and optimization of a series of 2-aminothiazole-oxazoles as potent phosphoinositide 3-kinase γ inhibitors.
    Oka Y; Yabuuchi T; Fujii Y; Ohtake H; Wakahara S; Matsumoto K; Endo M; Tamura Y; Sekiguchi Y
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7534-8. PubMed ID: 23122859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent developments of 2-aminothiazoles in medicinal chemistry.
    Das D; Sikdar P; Bairagi M
    Eur J Med Chem; 2016 Feb; 109():89-98. PubMed ID: 26771245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinazolinone analogs as potential therapeutic agents.
    Sharma PC; Kaur G; Pahwa R; Sharma A; Rajak H
    Curr Med Chem; 2011; 18(31):4786-812. PubMed ID: 21919847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced antitumor potential induced by chloroacetate-loaded benzophenones acting as fused tubulin-pyruvate dehydrogenase kinase 1 (PDHK1) ligands.
    Ghinet A; Thuru X; Floquet E; Dubois J; Farce A; Rigo B
    Bioorg Chem; 2020 Mar; 96():103643. PubMed ID: 32035298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quinoline as a privileged scaffold in cancer drug discovery.
    Solomon VR; Lee H
    Curr Med Chem; 2011; 18(10):1488-508. PubMed ID: 21428893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based de novo design and synthesis of aminothiazole-based p38 MAP kinase inhibitors.
    Park H; Lee S; Hong S
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3784-7. PubMed ID: 26259807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding patterns and structure-activity relationship of CDK8 inhibitors.
    Ma D; Chen X; Shen XB; Sheng LQ; Liu XH
    Bioorg Chem; 2020 Mar; 96():103624. PubMed ID: 32078847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromones: Privileged scaffold in anticancer drug discovery.
    Patil VM; Masand N; Verma S; Masand V
    Chem Biol Drug Des; 2021 Nov; 98(5):943-953. PubMed ID: 34519163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational Approaches Towards Kinases as Attractive Targets for Anticancer Drug Discovery and Development.
    Hameed R; Khan A; Khan S; Perveen S
    Anticancer Agents Med Chem; 2019; 19(5):592-598. PubMed ID: 30306880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.
    Furet P; Guagnano V; Fairhurst RA; Imbach-Weese P; Bruce I; Knapp M; Fritsch C; Blasco F; Blanz J; Aichholz R; Hamon J; Fabbro D; Caravatti G
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3741-8. PubMed ID: 23726034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Natural Product- and Privileged Scaffold-Based Tubulin Inhibitors Targeting the Colchicine Binding Site.
    Dong M; Liu F; Zhou H; Zhai S; Yan B
    Molecules; 2016 Oct; 21(10):. PubMed ID: 27754459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of selective aminothiazole aurora kinase inhibitors.
    Andersen CB; Wan Y; Chang JW; Riggs B; Lee C; Liu Y; Sessa F; Villa F; Kwiatkowski N; Suzuki M; Nallan L; Heald R; Musacchio A; Gray NS
    ACS Chem Biol; 2008 Mar; 3(3):180-92. PubMed ID: 18307303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QSAR and 3D-QSAR models in the field of tubulin inhibitors as anticancer agents.
    Marzaro G; Chilin A
    Curr Top Med Chem; 2014; 14(20):2253-62. PubMed ID: 25434357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.